Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O

Li, Yanmin; Aggarwal, Neeraj; Takamatsu, H.; Sterling, Catrina M.A.; Voyce, Charlotte; Barnett, P.V.

doi:10.1016/j.vaccine.2005.08.032

Cited by 32 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple cytokine has been tested as adjuvants of DNA vaccines. There is Table 2 showing the influence of various cytokine on FMDV DNA vaccine [12,38-44]. Based on a large number of tests, some cytokines were identified as effective adjuvants of DNA vaccines.…”

Section: Nucleic Acid Vaccinesmentioning

confidence: 99%

Research in advance for FMD Novel Vaccines

Zhang

Chen

et al. 2011

Virol J

View full text Add to dashboard Cite

Foot-and-Mouth Disease (FMD), as a major global animal disease, affects millions of animals worldwide and remains the main sanitary barrier to the international and national trade of animals and animal products. Inactivated vaccination is the most effective measure for prevention of FMD at present, but fail to induce long-term protection and content new requires for production of FMD vaccines. As a number of Researchers hope to obtain satisfactory novel vaccines by new bio-technology, novel vaccines have been studied for more than thirty years. Here reviews the latest research progress of new vaccines, summarizes some importance and raises several suggestions for the future of FMD vaccine.

show abstract

Section: Nucleic Acid Vaccinesmentioning

confidence: 99%

Research in advance for FMD Novel Vaccines

Zhang

Chen

et al. 2011

Virol J

View full text Add to dashboard Cite

show abstract

“…Current developments in the area of (improved) FMD vaccine types are based on: understanding the innate and cellular immune parameters (Barnard et al., 2005); induction of mucosal immunity (Summerfield et al., 2004); improving adjuvancy (Smitsaart et al., 2004); FMDV recombinant proteins (Wang et al., 2003), fusion proteins (Sun et al., 2003; Li et al., 2004) or proteins expressed in plants (Dus Santos et al., 2005); chimeric marker vaccines (Baranowski et al., 2001; Van Rensburg and Mason, 2002); consensus sequence peptides (Wang et al., 2002, 2004; Hohlich et al., 2003; Rodriguez et al., 2003; Beignon et al., 2005); vector‐based approaches that express part or all of the FMD empty capsid and/or cytokines, such as interferon‐alpha (Berinstein et al., 2000; Moraes et al., 2003, 2007; Pacheco et al., 2005; de Avila Botton et al., 2006); DNA vaccination strategies including protein Ag boost (Shao et al., 2005; Li et al., 2006) or the use of FMDV minigenes (Borrego et al., 2006); cytokine and Toll‐like receptor mRNAs in the nasal‐associated lymphoid tissues (Zhang et al., 2006). It often takes 5–10 years before a research idea makes its way to a commercial product.…”

Section: Types Of Vaccinementioning

confidence: 99%

FMD Vaccines: Reflections on Quality Aspects for Applicability in European Disease Control Policy

Clercq

Goris

Barnett

et al. 2008

Transboundary and Emerging Diseases

View full text Add to dashboard Cite

Most foot-and-mouth disease (FMD) vaccines used around the world are inactivated vaccines for prophylactic or emergency use, generally manufactured by the same basic methodology outlined in the OIE Manual and, for Europe, in the European Pharmacopoeia, and for the EU Member States in compliance with Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products as amended by Directive 2004/28/EC. Most of the requirements that apply to all immunological veterinary medicinal products apply equally to FMD vaccines. There are, however, some unique features of the disease and vaccines used against it that require a different approach to fulfil the requirements of the relevant legislation, if a vaccinate-to-live policy will be applied with 'authorized' vaccines. Several aspects of vaccine efficacy and safety are elaborated with emphasis on quality assurance/quality control (QA/QC). The purity of the vaccine in respect of the presence of non-structural protein antibodies could be checked indirectly by serology after vaccination. The viability of a vaccine bank approach was greatly aided by the principle of storing inactivated concentrated FMD viral antigen (Ag) over liquid nitrogen for subsequent formulation into vaccine. A worldwide Ag bank network might be an option for the far future and a solution to the problem of covering many different FMDV serotypes and strains. The producers should respect the strict FMD biosecurity rules worked out by the FAO EUFMD and described in Council Directive 2003/85/EC. Making the experience related to vaccine QA/QC available to all countries will reduce the risk of an FMD outbreak within these countries and consequently will reduce the FMD risk around the world.

show abstract

“…Although the inactivated virus vaccine usually elicits high levels of neutralizing antibodies and protection against the homologous virus, there are a number of concerns with the current vaccines, including the need for expensive high-containment manufacturing facilities to produce vaccines, incomplete viral inactivation, or virus escape from vaccine plants leading to vaccine related outbreaks [2,4,5]. Therefore, alternative vaccines that do not require live FMDV material, such as subunit vaccines, synthetic peptide vaccines, DNA vaccines, and recombinant virus vaccines, were extensively investigated [6][7][8][9][10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Construction and immune response characterization of a recombinant pseudorabies virus co-expressing capsid precursor protein (P1) and a multiepitope peptide of foot-and-mouth disease virus in swine

Qian

Zhang

et al. 2008

Virus Genes

View full text Add to dashboard Cite

Foot-and-mouth disease (FMD) is the most contagious and devastating disease of livestock. Our previous studies demonstrated that TK(-)/gG(-)/P1(+), a recombinant expressing the FMDV capsid precursor protein (P1) based on attenuated pseudorabies virus (PRV) TK(-)/gG(-), could be used as a recombinant vaccine to protect pigs against both pseudorabies and FMD. However, because the P1 expression cassette is inserted into the gG locus of the genome of PRV TK(-)/gG(-), this bivalent vaccine cannot be used in conjunction with the PRV gE-ELISA, an extensively used discriminatory serological test in eradication programs for pseudorabies, which limits the clinical use of this bivalent vaccine. To circumvent this shortcoming, in this study, an expression cassette containing synthetic multiepitope gene "FHG" consisting of six potential B cell epitopes and two potential T cell epitopes of FMDV, under the control of CMV promoter, was further inserted into the gE/gI locus of genome of TK(-)/gG(-)/P1(+), resulting in a new recombinant FHG/P1/PRV. The immunogenicity of FHG/P1/PRV was evaluated and compared with TK(-)/gG(-)/P1(+) in piglets. Our results clearly showed that FHG/P1/PRV performed better than or comparable with TK(-)/gG(-)/P1(+), as demonstrated by comparable PRV-specific neutralizing antibodies, enhanced FMDV-specific neutralizing antibodies, and cellular immune responses. More importantly, no gE- and gG-specific antibodies could be detected in pigs immunized with FHG/P1/PRV. These data indicate that FHG/P1/PRV is a promising bivalent vaccine candidate with more extensive potential application than TK(-)/gG(-)/P1(+) against both pseudorabies and FMD.

show abstract

Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O

Cited by 32 publications

References 16 publications

Research in advance for FMD Novel Vaccines

Research in advance for FMD Novel Vaccines

FMD Vaccines: Reflections on Quality Aspects for Applicability in European Disease Control Policy

Construction and immune response characterization of a recombinant pseudorabies virus co-expressing capsid precursor protein (P1) and a multiepitope peptide of foot-and-mouth disease virus in swine

Contact Info

Product

Resources

About